Sign Out
Splenic rupture, including fatal cases, has been reported following the administration of filgrastim. Individuals receiving filgrastim should report left abdominal and/or shoulder tip pain should be evaluated for enlarged spleen or splenic rupture.
Severe sickle cell crises, in some cases resulting in death, have been associated with the use of filgrastim in patients with sickle cell disorders. Only physicians qualified by specialized training or experience in the treatment of patients with sickle cell disorders should prescribe filgrastim for such patients, and only after careful consideration of the potential risks and benefits.
Continue with Google